{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:49:26Z","timestamp":1791139766308,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03746-y","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:57:24Z","timestamp":1738065444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-3591","authenticated-orcid":false,"given":"Elizabeth","family":"Lazaridou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9255-8196","authenticated-orcid":false,"given":"Zoe","family":"Apalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8347-218X","authenticated-orcid":false,"given":"Stylianos","family":"Ravanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-537X","authenticated-orcid":false,"given":"Garyfallia","family":"Stefanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Vellopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-4542","authenticated-orcid":false,"given":"Anastasios","family":"Tsolakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-9488","authenticated-orcid":false,"given":"Georgia","family":"Kourlaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"3746_CR1","doi-asserted-by":"crossref","unstructured":"Kamata M, Tada Y (2020) Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and their impact on comorbidities: a Literature Review. Int J Mol Sci.;21(5)","DOI":"10.3390\/ijms21051690"},{"issue":"5","key":"3746_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/09546634.2016.1255304","volume":"28","author":"J Lambert","year":"2017","unstructured":"Lambert J, Ghislain PD, Lambert J, Cauwe B, Van den Enden M (2017) Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). J Dermatolog Treat 28(5):394\u2013400","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"3746_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J et al (2014) Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 70(5):871\u2013881 e1-30","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"3746_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00403-009-0978-y","volume":"301","author":"A Nast","year":"2009","unstructured":"Nast A, Erdmann R, Hofelich V et al (2009) Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German psoriasis guidelines. Arch Dermatol Res 301(8):553\u2013559","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"3746_CR5","doi-asserted-by":"publisher","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","volume":"34","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Patel M, Li C, Garg V, Mandava MR, Wu JJ (2023) Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States. J Dermatolog Treat 34(1):2200870","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"3746_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Bryld LE, Skov L (2019) Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol 81(1):173\u2013178","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3746_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.19701","volume":"184","author":"T Graier","year":"2021","unstructured":"Graier T, Salmhofer W, Jonak C et al (2021) Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol 184(6):1094\u20131105","journal-title":"Br J Dermatol"},{"key":"3746_CR8","doi-asserted-by":"crossref","unstructured":"Ronholt K, Iversen L (2017) Old and New Biological therapies for Psoriasis. Int J Mol Sci.;18(11)","DOI":"10.3390\/ijms18112297"},{"issue":"4","key":"3746_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1684\/ecn.2011.0294","volume":"22","author":"A Michalak-Stoma","year":"2011","unstructured":"Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, Chodorowska G (2011) Cytokine network in psoriasis revisited. Eur Cytokine Netw 22(4):160\u2013168","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"3746_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","volume":"11","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA et al (2021) Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe Plaque Psoriasis: A Network Meta-analysis. Dermatol Ther (Heidelb) 11(3):885\u2013905","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"3746_CR11","doi-asserted-by":"publisher","first-page":"e12946","DOI":"10.1111\/sji.12946","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S (2020) The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol 92(4):e12946","journal-title":"Scand J Immunol"},{"key":"3746_CR12","doi-asserted-by":"publisher","unstructured":"Lazaridou E, Kourlaba G, Ravanidis S et al (2024) Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016\u20132020. Clin Exp Dermatol 49(12):1573\u20131581. https:\/\/doi.org\/10.1093\/ced\/llae240","DOI":"10.1093\/ced\/llae240"},{"issue":"2","key":"3746_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.18981","volume":"183","author":"ZZN Yiu","year":"2020","unstructured":"Yiu ZZN, Mason KJ, Hampton PJ et al (2020) Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol 183(2):294\u2013302","journal-title":"Br J Dermatol"},{"issue":"11","key":"3746_CR14","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y et al (2022) Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol 36(11):2101\u20132112","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3746_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M (2015) An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 28(6):390\u2013403","journal-title":"Dermatol Ther"},{"issue":"5","key":"3746_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","volume":"13","author":"YC Tsai","year":"2020","unstructured":"Tsai YC, Tsai TF (2020) Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol 13(5):493\u2013503","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"3746_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M et al (2016) Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 30(7):1148\u20131158","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"3746_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1080\/17512433.2021.1979394","volume":"14","author":"N Akdogan","year":"2021","unstructured":"Akdogan N, Dogan S, Bostan E et al (2021) Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis. Expert Rev Clin Pharmacol 14(12):1535\u20131541","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"3746_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","volume":"138","author":"IYK Iskandar","year":"2018","unstructured":"Iskandar IYK, Warren RB, Lunt M et al (2018) Differential Drug Survival of Second-Line Biologic therapies in patients with psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 138(4):775\u2013784","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3746_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1536867X0400400201","volume":"4","author":"V Coviello","year":"2004","unstructured":"Coviello V, Boggess M (2004) Cumulative incidence estimation in the Presence of competing risks. Stata J 4(2):103\u2013112","journal-title":"Stata J"},{"key":"3746_CR21","unstructured":"Naqvi A (2023) Stata package ``sankey\u2019\u2019 (Version 1.61)"},{"issue":"3","key":"3746_CR22","first-page":"201","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH (2015) Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm 21(3):201\u2013209","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"3746_CR23","first-page":"396","volume":"22","author":"SA Foster","year":"2016","unstructured":"Foster SA, Zhu B, Guo J et al (2016) Patient characteristics, Health Care Resource Utilization, and costs Associated with Treatment-Regimen failure with Biologics in the treatment of Psoriasis. J Manag Care Spec Pharm 22(4):396\u2013405","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"3746_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.16214","volume":"49","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA (2022) Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol 49(1):95\u2013105","journal-title":"J Dermatol"},{"issue":"9","key":"3746_CR25","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s13555-022-00775-1","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Xia Q, John AR, Patel V, Seigel L (2022) Treatment patterns for targeted Therapies, non-targeted therapies, and drug holidays in patients with psoriasis. Dermatol Ther (Heidelb) 12(9):2087\u20132103","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"3746_CR26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/jdv.12118","volume":"28","author":"U Mrowietz","year":"2014","unstructured":"Mrowietz U, de Jong EM, Kragballe K et al (2014) A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 28(4):438\u2013453","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"3746_CR27","doi-asserted-by":"publisher","first-page":"e33486","DOI":"10.1371\/journal.pone.0033486","volume":"7","author":"EA Brezinski","year":"2012","unstructured":"Brezinski EA, Armstrong AW (2012) Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS ONE 7(4):e33486","journal-title":"PLoS ONE"},{"key":"3746_CR28","first-page":"123","volume":"11","author":"P Hampton","year":"2021","unstructured":"Hampton P, Borg E, Hansen JB, Augustin M (2021) Efficacy of Brodalumab and Guselkumab in patients with moderate-to-severe Plaque Psoriasis who are inadequate responders to Ustekinumab: a matching adjusted Indirect comparison. Psoriasis (Auckl) 11:123\u2013131","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"3746_CR29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/09546634.2018.1427205","volume":"29","author":"L Sawyer","year":"2018","unstructured":"Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Moller A (2018) The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat 29(6):557\u2013568","journal-title":"J Dermatolog Treat"},{"key":"3746_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/ITT.S240891","volume":"10","author":"M Mosca","year":"2021","unstructured":"Mosca M, Hong J, Hadeler E, Hakimi M, Liao W, Bhutani T (2021) The role of IL-17 cytokines in Psoriasis. Immunotargets Ther 10:409\u2013418","journal-title":"Immunotargets Ther"},{"issue":"4","key":"3746_CR31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R et al (2021) Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for Psoriasis Treatment: a retrospective Multi-country, Multicentric Cohort Study. Am J Clin Dermatol 22(4):567\u2013579","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"3746_CR32","doi-asserted-by":"publisher","first-page":"e010","DOI":"10.1097\/JW9.0000000000000010","volume":"8","author":"C Guillet","year":"2022","unstructured":"Guillet C, Seeli C, Nina M, Maul LV, Maul JT (2022) The impact of gender and sex in psoriasis: what to be aware of when treating women with psoriasis. Int J Womens Dermatol 8(2):e010","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"3746_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jaad.2011.03.012","volume":"66","author":"J Wan","year":"2012","unstructured":"Wan J, Abuabara K, Troxel AB et al (2012) Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol 66(3):376\u2013386","journal-title":"J Am Acad Dermatol"},{"key":"3746_CR34","first-page":"213","volume":"12","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Maurelli M et al (2022) Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis (Auckl) 12:213\u2013220","journal-title":"Psoriasis (Auckl)"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03746-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T23:23:02Z","timestamp":1738106582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03746-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03746-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prescription data were anonymized prior to data extraction. Permission was obtained by the Ministry of Health, in accordance with the national legislation on the Protection of Individuals with regards to the Processing of Personal Data and with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"EL: Research grant to Aristotle University, Thessaloniki by Leo Pharma for the present study. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, participation on a Data Safety Monitoring Board or Advisory Board, and support for attending meetings and\/or travel from Abbvie, Novartis, Pfizer, UCB, Lilly, Sanofi, Genesis Pharma, Amgen, Janssen, Galderma, Galenica, Leo Pharma. ZA: Honoraria for lectures and for travels from Abbvie, Sanofi, Pfizer, Leo, Janssen, UCB. SR: employee of ECONCARE LP which had contracts with UCB, Abbvie, Leo, BMS. GS: employee of ECONCARE LP which had contracts with UCB, Abbvie, Leo, BMS. Payments from Aristotle University, Thessaloniki for this work. Contract with Pfizer via University of the Peloponnese for therapeutic area other than psoriasis. KV: employee of ECONCARE LP which had contracts with UCB, Abbvie, Leo, BMS. AT: None. KM: None. GK: Payments from Aristotle University, Thessaloniki for this work. Contract with Pfizer via University of the Peloponnese for therapeutic area other than psoriasis. Contracts with UCB, Abbvie, Leo, BMS via consulting firm.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}